




CORPORATE PROFILE



Daiichi-Sankyo

Corporate Profile

Daiichi Sankyo was established in 2005, after the merger of two leading century-old Japanese pharmaceutical companies. With more than 100 years of scientific expertise across a wide range of therapeutic categories, our new company draws upon a rich legacy of innovation and a robust pipeline of promising new compounds.

CREATING HOPE IN PATIENTS' LIVES



Daiichi Sankyo Company, Limited head office

Our Mission

To contribute to the enrichment of quality of life around the world through the creation and provision of innovative pharmaceuticals

Pharmaceutical innovation and therapeutic advances have had a dramatic impact on the lives of millions of people the world over.

While Daiichi Sankyo is proud to have been a part of this transformative era in human health, we realize that challenges remain. Treatments for many diseases are inadequate or non-existent, and patients and society are looking to our industry to provide effective, safe solutions that will improve their quality of life. It is at the intersection of research and patient need that we find our greatest challenges and our most extraordinary opportunities. It is where we direct our efforts and energies; it is at the heart of our mission.



Takashi Shoda
Representative Director, President and CEO



Daiichi Sankyo Strategies

Vision for 2015


It is our vision to establish Daiichi Sankyo as a true Global Pharma Innovator by 2015. Our ambitious growth targets will be met through the combined efficiencies of our merger and through our focused research and development programs in core disease areas: thrombotic disorders, malignant neoplasm, diabetes mellitus and autoimmune diseases/rheumatoid arthritis.

Our plan to consistently exceed the growth rate for the pharmaceutical industry will move us towards our 2015 financial target of ¥1.5 trillion (US\$14.9 billion/€10.5 billion)* in net sales, an operating income margin of 25 percent or more and an overseas sales ratio of more than 60 percent.

Our goals will be driven and met by scientific innovations—including the anti-platelet agent *Prasugrel* (Effient™/Efient®); *Edoxaban*, an anti-coagulant, and novel therapeutics in the oncology arena—and through strategic growth and expansion around the world.


* U.S. dollar and euro amounts are translated from yen solely for convenience at the rates of ¥100.5= US\$1 and ¥143.5=€1.

Strategic Direction



The Hybrid Business Model


Daiichi Sankyo's strength in developing and marketing proprietary products, combined with the non-proprietary drug capabilities of Ranbaxy Laboratories Ltd., a new Daiichi Sankyo affiliate, creates the Hybrid Business Model, extending our global reach into emerging markets and maximizing opportunities with a broad product portfolio. Through this Hybrid Business Model, Daiichi Sankyo is determined to realize sustainable growth, responding to medical needs around the world.



Daiichi Sankyo Strategies

Global R&D Network

Daiichi Sankyo is building a world-class global infrastructure to accelerate R&D activities in Japan, the United States and Europe. By utilizing the distinct development environments of each region, our goal is to file simultaneous NDA applications for extensive market penetration. In Japan, the R&D Division and the Pharmaceutical Technology Division form the nucleus of our R&D structure, while overseas global development activities are led by U.S.-based Daiichi Sankyo, Inc. and Daiichi Sankyo Development Ltd. in Europe.




GEMRAD

Expediting Decisions, Accelerating Development

An efficient and accelerated R&D pace demands an expedited model for identifying product candidates, determining financial commitments and ensuring efficient resource allocation.


Global Executive Meeting of Research And Development (GEMRAD) strives to accelerate development activities and ensure efficient resource allocation through effective management of R&D expenditures, rapid identification of potential development candidates and time-efficient decision-making. GEMRAD members represent a wide spectrum of corporate disciplines and specialties, including R&D, marketing, licensing and product portfolio management. This mix of skills, business and scientific expertise allows GEMRAD to make decisions based on comprehensive, cross-market assessments.



Daiichi Sankyo Global Outreach

Global Supply Chain Network


Daiichi Sankyo operates a globally integrated network to ensure that high quality, safe pharmaceutical products are supplied quickly for maximum value. Our supply chain of strategically positioned manufacturing plants in Japan, China, Germany, France, Taiwan, and Brazil—made larger through the addition of Ranbaxy Laboratories—offers seamless procurement, manufacturing and logistics. Our flexible and efficient supply chain structure ensures stable access to raw materials, systematic manufacturing and timely, reliable delivery.



Global Sales Force

The strength of our more than 5,000-person sales force provides timely and accurate information to clinicians on emerging medical issues and treatment trends. Possessing drive and expertise, these sales representatives will support new entries, such as Azor®/Sevikar®; combination antihypertensive of *Olmesartan medoxomil*, our flagship product, with *Amlodipine*, and the anti-platelet *Prasugrel* (Effient™/Efient®), while sustaining maximum sales for our established products.

Net Sales (for FY2008) and Number of Sales Representatives (as of March 31, 2009)





Research and Development

A Dynamic Pipeline


Daiichi Sankyo is committed to creating first-in-class and best-in-class therapies, and delivering these innovations as quickly and efficiently as possible to clinicians and patients who need them. In working towards this goal, we focus on our four core disease areas; thrombotic disorders, malignant neoplasm, diabetes mellitus and autoimmune diseases/rheumatoid arthritis, as well as the three franchise areas of hypertension, hyperlipidemia/atherosclerosis and bacterial infections.

Our R&D Division views its commitment through a “bench to bedside” lens, with a focus on efficiently translating our basic research findings into compounds with enormous therapeutic potential. Our pre-clinical, clinical and regulatory programs are designed to streamline the journey from discovery to development and approval. The Pharmaceutical Technology Division oversees the manufacture and supply of drug substances and products for clinical and non-clinical studies globally.



Products in Development

(as of July 31, 2009)



* Developed only in Japan

For the latest information on Daiichi Sankyo's R&D pipeline, please visit our website at:

www.daiichisankyo.com/ir/archive/index.html

A Legacy of Innovation


Daiichi Sankyo boasts a strong history of innovation and success in R&D, including our discovery and marketing of the first statin—a class of drug that transformed the treatment of hyperlipidemia and cardiovascular disease—as well as one of the first in a new and powerful class of anti-infectives.

In 1989, we launched *Pravastatin* (Mevalotin®) in Japan as the world's first water soluble, HMG-CoA reductase inhibitor, which has been used by millions of patients in more than 100 countries to treat hyperlipidemia. Similarly, the antihypertensive agent *Olmесartan medoxomil* (Olmotec® in Japan and Europe and Benicar® in the U.S.) is an angiotensin II receptor blocker (ARB) and proved to be highly effective in lowering blood pressure. Launched in the United States and Germany in 2002 and in Japan in 2004, *Olmесartan medoxomil* is helping patients in the treatment of hypertension in more than 50 countries improve and manage their health.

First launched in Japan in 1993, *Levofloxacin* (Cravit® in Japan, Levaquin® in the U.S. and Tavanic® in Europe) is one of the most trusted quinolones used in more than 120 countries. *Levofloxacin* is widely regarded among physicians because of its powerful antibacterial performance and broad-spectrum coverage against numerous diseases, accompanied with proven safety.

Healthier Future, Healthier World

Daiichi Sankyo is dedicated to listening, learning and making contributions that have a real impact on people's lives. Globally, our practices and activities are environmentally responsible. Regionally, we work with our employees to focus efforts on the health and well being of the underserved. Our philanthropic initiatives not only improve critical medical and healthcare services, but also support artistic, cultural and athletic activities for children, helping them create a fuller and more vibrant future.



For more details about our social, environmental and other CSR-related activities, please see our CSR Report (www.daiichisankyo.com/corporate/report/index.html)

Examples of Regional Programs



France

Repairing Children's Hearts

A program to raise funds for children's healthcare, organized by Daiichi Sankyo France SAS, was conducted from September 2006 to July 2007 in collaboration with Mécénat Chirurgie Cardiaque Enfants du Monde. This program enabled underprivileged children with heart deformities to undergo surgeries not available in their own countries. Our unique fundraising approach mobilized general practitioners, who participated in regional meetings that tested their cardiovascular knowledge. Correct answers garnered points, which were converted into euros. The events attracted more than 2,000 physicians and raised 32,000 euros, which was given to the organization in October 2007.

U.S.A.

Getting Medicines to Patients in Need

Our Open Care Patient Assistance Program and collaboration with the Partnership for Prescription Assistance (PPA) enable qualifying patients without prescription coverage to gain access to the medicines they need. Working with our philanthropy partners in the community, we sponsor a children’s museum science exhibit, donate books to underprivileged children to encourage reading, stock local food banks and fund operation of a mobile doctor’s office—the Highlands Health Van—that brings healthcare services to the uninsured. In addition, we have made significant donations to support a new cardiovascular institute at one of the top cardiac hospitals in the metropolitan NY/NJ area.



Brazil

Tackling Local Poverty

Daiichi Sankyo Brasil Farmacêutica LTDA. has a strong partnership with the Monte Azul Community Association (ACOMA) in Sao Paulo, which tackles the issue of local poverty and provides women’s healthcare and youth education. The company has also provided a portion of its business profits to emergency outpatients, donated funds to help support monthly building maintenance and assisted with a job training project for teenagers.



Japan

Creating Hope for Students through Scientific Experience

Daiichi Sankyo supports enhancing students’ interests in math and science. The company holds a variety of events to cultivate scientific interest in youth, such as hosting science classes for elementary school students, pharmacology seminars for high school students and internship programs at university labs.




Corporate Governance

We place a high priority on corporate governance practices to ensure that our business activities comply with standards of care as well as global and domestic regulations. We also pride ourselves on our ability to be flexible and to adapt quickly to changes in the business environment. Daiichi Sankyo has established internal governance policies that include the Daiichi Sankyo Group Corporate Conduct Charter and Standards of Conduct for Compliance, to ensure sound management based on regulatory compliance. A vital component of this structure is our governance organization consisting of directors and auditors. Our 10-member Board of Directors, including four external directors, ensures sound and appropriate business operations and quick decision-making.

Integral to our governance is a corporate officer system in which corporate officers are

appointed by the Board of Directors to perform specific duties under the direction of the President. Individuals appointed as corporate officers have a high level of expertise in their specific business fields. Additionally, Daiichi Sankyo has adopted a corporate auditor system in which the Board of Corporate Auditors, consisting of four corporate auditors including two outside auditors, verifies the legality and soundness of management decisions. Each corporate auditor provides guidance in accordance with the corporate audit standards and verifies the details of reports received from directors and others and investigates the state of business and property of the company. The Internal Audit Department implements group-wide internal audits of the compliance system, risk management system, internal control system and other areas in accordance with the company's audit plan.



History

Sankyo Co., Ltd.

1899

- Founding of Sankyo Shoten jointly financed by Matasaku Shiobara (photo), Shotaro Nishimura and Genjiro Fukui
- Launched digestive enzyme Taka-Diastase® based on a discovery by Dr. Jokichi Takamine



1910

- Dr. Umetaro Suzuki discovered vitamin B1 (Orizantin®) from rice bran, establishing the basis for the theory of vitamins



1913

- Established Sankyo Co., Ltd.
- Dr. Jokichi Takamine became the first president



1949

- Listed on Tokyo Stock Exchange

1951

- Launched Lulu® (OTC medicine), cold medicine (photo)
- Manufactured the first domestically produced antibiotic preparation Chloromycetin®



1961

- Established a representative office in New York

1963

- Established a representative office in Basel, Switzerland



1983

- Launched Captoril®, the world's first renin-angiotensin-type antihypertensive agent

1985

- Established Sankyo USA Corporation (New York, U.S.A.)
- Established Sankyo Europa GmbH (Dusseldorf, West Germany)

1989

- Launched Mevalotin®, an HMG-CoA reductase inhibitor (antihyperlipidemic agent)



1990

- Acquired the Luitpold Werke group in Munich, Germany

2002

- Launched antihypertensive agent Olmesartan medoxomil in the U.S. and Germany (marketed as Benicar® and Olmetec®, respectively) as a strategic global product



1900

1950

1960

1970

1980

1990

2000

Daiichi Pharmaceutical Co., Ltd.

1915

- Founding of Arsemin Shokai by Dr. Katsuzemon Keimatsu and others



1918

- Established Daiichi Pharmaceutical Co., Ltd.
- Seinosuke Shibata appointed as first president



1921

- Launched Bosmin®, a vasoconstriction/hemostasis and asthma medicine



1937

- Launched Therapol®, the first domestically produced Sulfa



1962

- Launched the world's first anti-plasmin medicine Ipsilon®

1966

- Launched Patecs®, the first shape-forming poultice (OTC medicine)



1980

- Established a representative office in New York

1990

- Established Korea Daiichi Pharmaceutical Co., Ltd.

1993

- Launched Cravit®, a broad-spectrum oral antibacterial agent
- Established Daiichi Pharmaceutical UK Ltd.



1998

- Established Daiichi Pharmaceutical (Beijing) Co. Ltd. in China

Daiichi Sankyo Company, Limited

Apr. 2007



2005

- Establishment of Daiichi Sankyo Company, Limited as a joint holding company

2006

- Started operations of Daiichi Sankyo Healthcare Co., Ltd.
- Started operations of Daiichi Sankyo, Inc., the new U.S. organization
- Started operations of Daiichi Sankyo Europe GmbH, the new European organization

2007

- Started operations as the newly formed Daiichi Sankyo Company, Limited

Daiichi + Sankyo Synergies

In April 2007, Daiichi Sankyo started operations as a single organization. By combining the unique strengths of the former Daiichi and Sankyo, we are realizing synergies as a leader in our fields of expertise based on the philosophy of "first-in-class, best-in-class." This integration strengthens the R&D infrastructure needed to maintain a steady flow of new products by combining the creative energies of our researchers and enabling more efficient R&D investments in fields of specialization. The integration also bolsters our domestic and overseas sales forces and distribution networks.



www.daiichisankyo.com

Contact List

Japan	DAIICHI SANKYO COMPANY, LIMITED 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan Tel. +81-3-6225-1111
USA	DAIICHI SANKYO, INC. Two Hilton Court, Parsippany, NJ 07054, U.S.A. Tel. +1-973-944-2600
Europe	DAIICHI SANKYO EUROPE GmbH Zielstattstrasse 48, 81379 Munich, Germany Tel. +49-89-7808-0